Litigation Details for EPI Health, LLC v. Padagis Israel Pharmaceuticals Ltd (D. Del. 2021)

« Back to Dashboard

EPI Health, LLC v. Padagis Israel Pharmaceuticals Ltd (D. Del. 2021)

Docket		Date Filed	2021-04-05
Court	District Court, D. Delaware	Date Terminated	2021-09-14
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	10,335,391; 10,751,325; 7,812,049; 8,420,688; 8,815,929; 8,883,838; 9,974,773
Link to Docket	External link to docket

Details for EPI Health, LLC v. Padagis Israel Pharmaceuticals Ltd (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-04-05				External link to document
2021-04-05	4	Patent/Trademark Report to Commissioner of Patents	B2 ;8,815,929 B2 ;8,883,838 B2 ;9,974,773 B2 ;10,335,391 B2 ;10,751,325 B2. (mal) (Entered: 04/06/2021… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,812,049 B2 ;… 14 September 2021 1:21-cv-00498 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2021-04-05	41	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,812,049 B2; 8,420,688 B2 ;8,815,929… 14 September 2021 1:21-cv-00498 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

EPI Health v. Padagis Israel Pharmaceuticals: Litigation Summary, Patent Claims, and Generic Entry Analysis

Last updated: August 21, 2026

EPI Health, LLC v. Padagis Israel Pharmaceuticals Ltd., No. 1:21-cv-00498, was a Hatch-Waxman patent infringement action in the U.S. District Court for the District of Delaware concerning a proposed generic version of Wynzora Cream, a topical calcipotriene and betamethasone dipropionate product. EPI Health asserted patents covering the product’s topical formulation against Padagis after Padagis submitted an abbreviated new drug application, or ANDA, to the FDA.

The case was resolved without a publicly reported merits judgment. The litigation therefore created a regulatory delay and settlement-driven entry risk rather than producing a judicial ruling defining the ultimate scope or validity of the asserted patents.

What drug and FDA product were at issue in EPI Health v. Padagis?

The dispute concerned Wynzora Cream, a topical formulation containing calcipotriene and betamethasone dipropionate.

Product	Information
Brand	Wynzora Cream
Active ingredients	Calcipotriene and betamethasone dipropionate
Dosage form	Topical cream
Strength	Calcipotriene 0.005% and betamethasone dipropionate 0.064%
FDA application	NDA No. 215236
FDA approval	July 20, 2020
Indication	Topical treatment of plaque psoriasis in adults
Brand owner and commercial interests	MC2 Therapeutics and EPI Health
Proposed generic pathway	ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act

Wynzora uses a proprietary cream formulation intended to improve topical delivery and cosmetic characteristics compared with conventional ointments or suspensions. The formulation technology was central to the patent dispute, rather than the basic therapeutic activity of either active ingredient.[1]

What patents protected Wynzora Cream in the Padagis litigation?

EPI Health’s complaint asserted formulation-related patents associated with Wynzora Cream. The patents addressed topical pharmaceutical compositions containing calcipotriene and corticosteroid components, including formulation characteristics and delivery properties.

The public litigation record identifies the asserted patent estate as covering the commercial formulation rather than merely the chemical identity of calcipotriene or betamethasone dipropionate. This distinction matters because the active ingredients are old, while the commercial value rests in the formulation, stability, delivery, and patient-use characteristics.

What type of patent claims were asserted?

The asserted claims generally fell into the following categories:

1. Composition claims covering topical formulations containing calcipotriene and betamethasone dipropionate.
2. Formulation claims directed to the physical and chemical properties of the cream.
3. Delivery-related claims addressing the use of the formulation on psoriatic skin.
4. Method-of-use claims directed to treating plaque psoriasis.

The case did not concern a biologic product. Biosimilar substitution rules therefore were not relevant. The principal competitive threat was an ANDA generic, subject to the Hatch-Waxman framework and FDA Orange Book patent certifications.

When did EPI Health file the case against Padagis?

EPI Health filed the action in the District of Delaware in 2021 under case number 1:21-cv-00498. The complaint followed Padagis’s filing of an ANDA seeking approval to market a generic version of the listed Wynzora product.

The lawsuit was based on the Paragraph IV certification process. Padagis took the position that the relevant Orange Book-listed patents were invalid, unenforceable, or would not be infringed by the proposed generic product. EPI Health treated the certification as an act of infringement under 35 U.S.C. § 271(e)(2).

What does a Paragraph IV challenge mean in this case?

A Paragraph IV certification allows an ANDA applicant to assert that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The certification gives the patent holder an opportunity to sue before generic approval.

Once a timely patent infringement action is filed, FDA approval of the ANDA is generally subject to a statutory 30-month stay, unless the court issues a different order or the litigation is resolved earlier. The stay is a regulatory consequence of the lawsuit, not a finding that the patents are valid.

What was the legal strategy of EPI Health?

EPI Health’s strategy was to enforce formulation patents before FDA approval of Padagis’s ANDA. The action sought the standard Hatch-Waxman remedies:

• A declaration that the ANDA product would infringe the asserted patents.
• An injunction preventing commercial manufacture, use, offer for sale, sale, or importation before patent expiration.
• A prohibition on FDA approval of the ANDA before the expiration of the asserted patents.
• Costs and other relief available under the patent laws.

The commercial objective was to preserve Wynzora’s branded market position while the Orange Book patents remained enforceable.

What was Padagis’s defense?

Padagis’s ANDA certification placed the core patent issues into the case. Its defenses would have included noninfringement and invalidity, with the precise defenses determined by the ANDA notice and pleadings.

For a topical formulation case, the principal technical disputes typically concern:

• Whether the generic contains every limitation of the asserted composition claims.
• Whether formulation ingredients fall within claimed concentration ranges.
• Whether the generic has the claimed physical properties.
• Whether the asserted claims are anticipated or obvious in view of earlier topical psoriasis products.
• Whether written description and enablement requirements are satisfied.
• Whether any patent term or listing issue limits the available relief.

The public resolution of the case did not produce a reported claim-construction opinion or trial decision. Padagis therefore did not receive a judicial ruling invalidating the asserted patents, and EPI Health did not receive a judicial ruling confirming infringement.

Was the case decided on the merits?

No publicly reported merits decision resolved the patent validity or infringement questions. The case ended through a negotiated resolution rather than a final trial judgment.

The absence of a merits decision has several implications:

• The asserted patents were not judicially confirmed as valid.
• Padagis was not judicially found to infringe.
• The litigation did not establish binding claim-construction precedent.
• The parties’ commercial agreement, including any permitted launch date, was not fully disclosed in the public record.
• The settlement did not necessarily resolve all patents that could later be listed for Wynzora or asserted against other ANDA applicants.

What was the settlement status?

The action was resolved and closed without a reported public damages award or injunction following trial. The principal commercial terms of the settlement were not publicly disclosed.

In Hatch-Waxman cases, settlement terms can address:

• The date on which the generic may launch.
• Whether launch is authorized before all asserted patent expirations.
• Supply, licensing, or manufacturing arrangements.
• Restrictions on authorized generic competition.
• Allocation of litigation costs.
• Treatment of future patent listings or continuation patents.

The absence of disclosed terms prevents a definitive public determination of Padagis’s agreed launch date. A docket termination therefore should not be interpreted as evidence that Padagis received immediate approval or unrestricted market entry.

What was the Orange Book status of Wynzora?

Wynzora was approved under NDA No. 215236 and associated patents were listed in the FDA Orange Book. Those listings provided the statutory basis for Paragraph IV litigation against ANDA applicants.

Orange Book protection for Wynzora is formulation-driven. The underlying active ingredients are genericized pharmaceutical substances, so the commercial patent barrier depends on the surviving scope of the listed formulation and method-of-use claims.

How does Orange Book listing affect generic approval?

An Orange Book listing can create a 30-month FDA approval stay after a timely patent infringement action. The stay delays approval but does not itself extend the patent term.

The key regulatory events are:

Event	Consequence
ANDA filing with Paragraph IV certification	Creates potential patent litigation
Notice to NDA holder and patent owner	Starts the 45-day period for filing suit
Timely infringement complaint	Generally triggers a 30-month FDA stay
Settlement or dismissal	May end the litigation without resolving validity
Patent expiration or final FDA approval eligibility	Removes the principal patent-based approval barrier

FDA approval may also be affected by pediatric exclusivity, regulatory exclusivity, amendments to the ANDA, or additional Orange Book-listed patents.

How strong was the Wynzora patent estate?

The Wynzora estate had moderate commercial strength because it protected a differentiated topical formulation rather than a new molecular entity. Its value depended on whether the asserted claims were broad enough to cover competing cream formulations and narrow enough to withstand obviousness and written-description attacks.

Strengths of the estate

• The product used a proprietary topical delivery system.
• The active ingredients were combined in a formulation with differentiated physical properties.
• Formulation claims can create a practical barrier even when the active ingredients are old.
• ANDA litigation delayed approval and increased the cost of generic development.
• A generic applicant may need to design around multiple composition limitations.

Weaknesses of the estate

• Calcipotriene and betamethasone dipropionate have extensive prior-art histories.
• Topical psoriasis products provide a substantial obviousness landscape.
• Narrow concentration, excipient, or physical-property limitations can permit noninfringing design-arounds.
• A formulation patent does not necessarily block all alternative dosage forms or delivery systems.
• Settlement without a merits decision leaves validity and enforceability untested.

The estate was therefore more durable against a direct copy of Wynzora’s formulation than against a materially different cream, ointment, foam, gel, or suspension.

What generic entry risks existed for Wynzora?

The most immediate risk was a direct generic cream approved through the ANDA pathway. A successful Padagis challenge could have reduced Wynzora pricing and market share rapidly because topical dermatology products are often exposed to substitution after generic approval.

Generic launch scenarios

Scenario	Likely commercial effect
Padagis loses or settles for a late launch	Preserves branded pricing until the agreed or patent-based date
Padagis obtains approval after patent expiry	Creates conventional generic price erosion
Padagis launches under a license	May create earlier but controlled erosion
Padagis designs around the asserted claims	Could obtain approval without infringing the litigated patents
Additional ANDA applicants enter	Increases price pressure and reduces the value of a single settlement

The most important unresolved commercial variable was the settlement launch date. A confidential early-entry license can have materially different consequences from a launch tied to the latest asserted patent expiration.

Which companies were positioned to challenge Wynzora?

Padagis was the defendant in the identified action. Other generic dermatology companies could pursue ANDA or alternative regulatory strategies depending on the Orange Book listings, formulation patents, and the availability of noninfringing formulations.

Potential competitors in the topical psoriasis market include manufacturers with established dermatology portfolios, such as:

• Teva Pharmaceuticals and Padagis.
• Perrigo.
• Amneal Pharmaceuticals.
• Taro Pharmaceuticals.
• Glenmark Pharmaceuticals.
• Prasco Laboratories.
• Dr. Reddy’s Laboratories.
• Lupin.

A company seeking to avoid the Wynzora patent estate could develop a different formulation or pursue a product that is not therapeutically equivalent to the branded cream. Such products would compete commercially but would not necessarily qualify for automatic pharmacy substitution.

How does Wynzora compare with competing topical psoriasis products?

Wynzora competes with older calcipotriene and corticosteroid products, as well as newer branded topical therapies.

Product category	Active treatment	Patent risk	Substitution risk
Wynzora Cream	Calcipotriene plus betamethasone dipropionate	Formulation and method-of-use patents	High after ANDA approval
Taclonex products	Calcipotriene plus betamethasone dipropionate	Older formulation estates	Dependent on product and formulation
Calcipotriene generics	Calcipotriene	Limited active-ingredient protection	High
Betamethasone generics	Corticosteroid	Limited active-ingredient protection	High
Vtama cream	Tapinarof	Newer product-specific patent estate	Lower initially
Zoryve cream or foam	Roflumilast	Product and formulation patents	Lower initially
Topical corticosteroids	Various corticosteroids	Generally mature estates	High

Wynzora’s differentiation is formulation and administration convenience. Its exposure to generic competition remains significant because the active ingredients and therapeutic class are mature.

What revenue exposure did the litigation create?

A generic launch would likely affect Wynzora through three channels:

1. Lower net price from payer and pharmacy substitution.
2. Reduced prescription volume as formularies favor lower-cost alternatives.
3. Higher rebate requirements to preserve formulary access.

The magnitude of revenue loss would depend on the launch date, number of generic entrants, whether the generic was therapeutically equivalent, and whether the brand retained exclusivity through authorized-generic or licensing arrangements.

The case did not produce a public damages judgment quantifying EPI Health’s exposure. Commercial impact therefore depends on the negotiated launch terms and the timing of other competitors.

Did the case create biosimilar risk?

No. Biosimilar risk was not implicated because Wynzora is a small-molecule topical drug approved under an NDA, not a biologic licensed under a biologics license application.

The relevant competitive pathway was ANDA approval and generic substitution. The legal and regulatory analysis is therefore different from that applicable to insulin, monoclonal antibodies, or other biologic products.

What manufacturing and intellectual-property barriers remain?

The main manufacturing barrier is the ability to reproduce a stable, pharmaceutically acceptable topical formulation with equivalent performance. A generic applicant must satisfy FDA requirements for pharmaceutical equivalence and bioequivalence or other applicable equivalence standards.

The main intellectual-property barriers are:

• Formulation composition claims.
• Concentration and ratio limitations.
• Physical-property limitations.
• Manufacturing-process claims.
• Method-of-use claims.
• Continuation and divisional patents that may create later-filed enforcement positions.

A formulation patent can be commercially important even when it does not block every alternative product. Its value is highest when the claimed formulation is closely aligned with the FDA-approved product and difficult to design around without losing therapeutic or manufacturing performance.

What is the current litigation significance of EPI Health v. Padagis?

The case is commercially important as an example of formulation-centered Hatch-Waxman enforcement for a topical dermatology product. Its outcome did not generate a precedential ruling on patent validity, claim construction, or infringement.

For diligence purposes, the key conclusions are:

• The litigation involved an ANDA challenge to Wynzora.
• The asserted protection focused on the commercial topical formulation.
• The case was resolved without a public merits judgment.
• Settlement terms and the precise permitted generic entry date were not publicly disclosed.
• Generic risk remains tied to the durability of the Orange Book-listed formulation estate and the possibility of additional challengers.
• No biosimilar framework applies.

Key Takeaways

• EPI Health v. Padagis, No. 1:21-cv-00498, was a District of Delaware Hatch-Waxman case involving Wynzora Cream.
• Padagis challenged Orange Book-listed patents through the Paragraph IV process.
• EPI Health relied on formulation and related method-of-use protection.
• The case ended without a reported trial decision or judicial finding of validity and infringement.
• Settlement terms, including any authorized generic launch date, were not publicly disclosed.
• The principal risk is conventional ANDA generic competition, not biosimilar substitution.
• The patent estate is strongest against direct copies of the Wynzora formulation and weaker against technically differentiated topical products.
• Wynzora’s commercial exposure depends on the settlement structure, additional ANDA filings, and the expiration or survival of formulation patents.

FAQs About EPI Health v. Padagis

What was EPI Health suing Padagis over?

EPI Health sued Padagis over Padagis’s proposed generic version of Wynzora Cream, a calcipotriene and betamethasone dipropionate topical product.

Was Padagis found to infringe Wynzora patents?

No reported merits judgment found Padagis liable for infringement. The action was resolved without a public trial decision.

Did Padagis receive an immediate generic launch right?

The public record does not disclose a definitive immediate-launch authorization. The case resolution did not publicly establish the commercial launch date.

Are Wynzora patents listed in the FDA Orange Book?

Yes. Wynzora was approved under NDA No. 215236, and associated patent listings supported the Paragraph IV litigation.

Can a different topical formulation avoid the Wynzora patents?

Potentially. A product that does not meet every limitation of the asserted formulation or method-of-use claims may avoid infringement, although it may also fail to qualify as an automatically substitutable generic Wynzora equivalent.

References

1. U.S. Food and Drug Administration. (2020). Wynzora Cream, NDA No. 215236: Approval information and prescribing information. FDA Drugs@FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. U.S. District Court for the District of Delaware. (2021). EPI Health, LLC v. Padagis Israel Pharmaceuticals Ltd., No. 1:21-cv-00498. Civil docket and pleadings.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center: U.S. patent prosecution and patent-document records. USPTO.

5. U.S. Code. (2023). 35 U.S.C. § 271(e)(2): Infringement based on submission of an abbreviated new drug application. Legal Information Institute.